Your partner in oncology

oncology therapeutic development

A boutique CRO focused solely on oncology and onco-hematology.


Specialized in early development of single agent and combination anticancer regimens.


Independent consulting services in oncology early drug development.


Collective experience managing over 60 Phase I-II oncology clinical trials.


  • Rapid and efficient development of promising new cancer treatments
  • Clinical/preclinical consulting for biotechs and VC groups to guide clinical development
  • Optimize, launch and effectively execute your clinical development plan
  • Interactive support for small and mid-size partners via strong medical input from oncology-experienced staff



  • Execute clinical oncology Phase I/II study design and implementation
  • Real-time data evaluation with continuous oncology input
  • Generate quality data with timely, efficient and cost-effective execution

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda M, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M.  Oncotarget . 2017;31;8(5):7598-613.

Go to publication

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.  Oncotarget . 2016;7(48):79637-53.

Go to publication

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.

Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R.  Int J Cancer . 2017;140(1):197-207.

Go to publication

Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628.

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA. Cancer Discov. 2016;6(5):492-500.

Go to publication

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Lancet Haematol. 2016;3(4):e196-204.

Go to publication

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.  Lancet Haematol . 2016;3(4):e186-95.

Go to publication
Clikeo Agence Clikeo